1. Home
  2. INAB vs ZBAI Comparison

INAB vs ZBAI Comparison

Compare INAB & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INAB
  • ZBAI
  • Stock Information
  • Founded
  • INAB 2016
  • ZBAI 2015
  • Country
  • INAB United States
  • ZBAI United States
  • Employees
  • INAB N/A
  • ZBAI N/A
  • Industry
  • INAB Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • INAB Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • INAB Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • INAB 14.5M
  • ZBAI 17.3M
  • IPO Year
  • INAB 2021
  • ZBAI N/A
  • Fundamental
  • Price
  • INAB $4.17
  • ZBAI $0.49
  • Analyst Decision
  • INAB Strong Buy
  • ZBAI
  • Analyst Count
  • INAB 2
  • ZBAI 0
  • Target Price
  • INAB $3.60
  • ZBAI N/A
  • AVG Volume (30 Days)
  • INAB 7.9M
  • ZBAI 962.4K
  • Earning Date
  • INAB 05-07-2025
  • ZBAI 03-13-2025
  • Dividend Yield
  • INAB N/A
  • ZBAI N/A
  • EPS Growth
  • INAB N/A
  • ZBAI N/A
  • EPS
  • INAB N/A
  • ZBAI N/A
  • Revenue
  • INAB N/A
  • ZBAI $670,000.00
  • Revenue This Year
  • INAB N/A
  • ZBAI N/A
  • Revenue Next Year
  • INAB N/A
  • ZBAI N/A
  • P/E Ratio
  • INAB N/A
  • ZBAI N/A
  • Revenue Growth
  • INAB N/A
  • ZBAI 67.50
  • 52 Week Low
  • INAB $0.10
  • ZBAI $0.47
  • 52 Week High
  • INAB $4.17
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • INAB 98.72
  • ZBAI N/A
  • Support Level
  • INAB $0.10
  • ZBAI N/A
  • Resistance Level
  • INAB $0.19
  • ZBAI N/A
  • Average True Range (ATR)
  • INAB 0.11
  • ZBAI 0.00
  • MACD
  • INAB 0.26
  • ZBAI 0.00
  • Stochastic Oscillator
  • INAB 100.00
  • ZBAI 0.00

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: